Pieter Spee
Chief Technology Officer
FIBROTX Innovations for skin
Europe
Biography
Pieter Spee has received his PhD in immunology from the Netheralands Cancer Institute/University of Leiden (NL). While at Novo Nordisk, he made significant contributions to Lirilumab and Monalizumab, both currently in phase II clinical development by BMS and AstraZeneca in collaboration with Innate Pharma, respectively. As a Director and Scientific Director he was heading up preclinical translational research at Novo Nordisk. In 2012, he founded PS! Pharmaconsult, offering expert advise on drug and medical device development through a unique 360 degrees patient centric approach. Currently, he functions as chief technology officer at FibroTx LLC, developing two highly innovative skin diagnostic devices, TAP and SELF, allowing personalized medicine in skin care and clinical dermatology.
Research Interest
Clinical Dermatology,Skin care Products